Navigation Links
Novadaq Reports Financial Results for the First Quarter of 2008
Date:5/12/2008

TORONTO, May 12 /PRNewswire-FirstCall/ - Novadaq(R) Technologies Inc. (TSX: NDQ), a developer of real-time imaging and image guidance systems for use in the operating room, today announced financial results for the first quarter ended March 31, 2008. In this press release, unless otherwise indicated, all dollar amounts are expressed in US dollars.

Q1 2008 Highlights

- SPY gaining traction with 14 new SPY systems installed, 22% increase

in SPY consumable sales and 20% increase in SPY capital revenue from

Q4 2007.

- Sentara Hospital System, Virginia's largest cardiac surgery program

completes multiple SPY System capital purchase and adopts SPY as

standard of care.

- SPY adopted in 9 leading plastic and reconstructive surgery centers

(including Cleveland Clinic, Duke University, and University of

Southern California) since Q4 2007 launch.

- SPY Scope testing in large animal model continues to demonstrate

efficacy of SPY imaging in minimally invasive surgery applications

and is on-track for human trials in Q4 2008.

Events Subsequent to Q1 2008

- Positive results from two European centers using OPTTX presented at

the Association for Research in Vision and Ophthalmology annual

meeting support OPTTX partnership opportunities.

"I am pleased with the developing fundamentals of the SPY business as we had our best quarter for SPY placements, and showed strong growth in consumable and capital sales." said Dr. Arun Menawat, President and Chief Executive Officer of Novadaq Technologies Inc. "Plastic surgery has been a catalyst in accelerating SPY adoption, and continued growth in SPY will be supported by the launch of quantification software in the second half of 2008 and by our continued support in getting surgeons paid for SPY procedures."

Financial Results

Quarter Ended March 31, 31,

2008 2007

$ $

--------------------------

OPERATING ACTIVITIES

Net loss for the period (4,838,932) (3,701,133)

Add items not involving cash

Depreciation and amortization 586,845 368,599

Stock option compensation 177,261 93,212

--------------------------

(4,074,826) (3,239,322)

Net change in non-cash working capital

balances related to operations 2,488,832 (217,612)

--------------------------

Cash provided by (used in) operating

activities (1,585,994) (3,456,934)

--------------------------

FINANCING ACTIVITIES

Issuance of common shares, net 25,000 -

--------------------------

Cash provided by financing activities 25,000 -

--------------------------

INVESTING ACTIVITIES

Research and development costs - (37,892)

Purchase of plant, property and equipment (435,987) (515,766)

Purchase of TMR business (2,089,284) (2,386,117)

Sale of short-term investments, net 4,182,398 4,691,291

--------------------------

Cash provided by investing activities 1,657,127 1,751,516

--------------------------

Net increase (decrease) in cash and cash

equivalents during the period 96,133 (1,705,418)

Cash and cash equivalents, beginning of period 7,417,929 2,311,973

--------------------------

Cash and cash equivalents, end of period 7,514,062 606,555

--------------------------

--------------------------

2008 "Q1-2008" Compared to Quarter Ended

March 31, 2007 "Q1-2007"

Revenue increased to approximately $2,773,000 in Q1-2008 from approximately $1,427,000 in Q1-2007. Recurring revenue, which includes SPY and TMR consumables, rentals and parts increased from approximately $693,000 in Q1-2007 to $1,496,000 in Q1-2008. The primary reason for the increase is that TMR consumable revenue was recognized for a full quarter in 2008. Capital sale revenue increased from approximately $734,000 in Q1-2007 to $919,000 in Q1-2008, as an increase in SPY capital of $540,000 was partly offset by a decrease in TMR capital of $363,000. Service revenue, which increased from nil in Q1-2007 to approximately $358,000 in Q1-2008 relates partly to the TMR business which was acquired in the last few days of Q1-2007, and to PINPOINT, which was acquired after Q1-2007.

Recurring revenue and service revenue increased from Q4-2007 to Q1-2008 whereas capital sale revenue decreased, as an increase in SPY capital sale revenue was more than offset by decreases in TMR and PINPOINT capital revenue.

Gross profit increased to approximately $1,305,000 in Q1-2008 from approximately $679,000 in Q1-2007 as a result of the increase in revenue described above. Gross profit as a percent of sales was substantially unchanged.

Sales and marketing expenses increased by approximately $567,000 to approximately $2,784,000 in Q1-2008 from approximately $2,217,000 in Q1-2007 due to expansion of a direct sales team through 2007 and into 2008. $242,000 of the increase occurred from Q4-2007 to Q1-2008.

Research and development expenses increased by approximately $317,000 to approximately $1,612,000 in Q1-2008 from approximately $1,295,000 in Q1-2007. The increase relates primarily to the establishment of a research and development center in Vancouver B.C. staffed by former employees of Xillix. Research and development expenses in Q1-2008 increased by $79,000 from Q4-2007. The increase related primarily to patent costs.

General and administration expenses increased by approximately $581,000 to approximately $1,459,000 in Q1-2008 from $878,000 in Q1-2007. Increases relate primarily to costs incurred to defend patents in Japan and general increases to support a direct sales team, and the acquired TMR business. General and administrative expenses in Q1-2008 decreased by $50,000 from Q4-2007 due to lower professional fees.

Depreciation expense increased to approximately $89,000 in Q1-2008 from approximately $52,000 in Q1-2007 primarily as a result of computer equipment purchased in 2007 for sales representatives hired during the period. Depreciation expense in Q1-2008 was generally consistent with Q4-2007.

Amortization increased by from $121,000 in Q1-2007 to $308,000 in Q1-2008 as a result of the acquisition of intangibles related to TMR and Xillix. Amortization in Q1-2008 was slightly higher than amortization in Q4-2007 because the final earn out amount associated with the TMR acquisition was calculated effective December 31, 2007.

The Company had interest expense in Q1-2007 of approximately $9,000 relating to a $3,000,000 note payable issued on March 20, 2007 in connection with the acquisition of TMR distribution rights. The note was repaid in 2007 and there was no interest expense in Q1-2008.

Interest income decreased by approximately $36,000 to $158,000 in Q1-2008 from $194,000 in Q1-2007. The primary reason was lower interest rates.

Net loss increased by approximately $1,138,000 to approximately $4,839,000 in Q1-2008 from approximately $3,701,000 in Q1-2007 primarily as a result of an increase in sales and marketing costs of approximately $567,000, an increase in R&D expenses of approximately $317,000, an increase in general and administrative expenses of approximately $581,000 which were partly offset by an increase in gross profit of $626,000.

As at March 31, 2008 the Company had cash, cash equivalents and short-term investments of approximately $14,775,000, a decrease of approximately $4,086,000 from December 31, 2007. Approximately $4,075,000 of the decrease relates to a net loss incurred during the period after deducting items not involving cash, a source of approximately $2,489,000 in net changes in non-cash working capital relating primarily to the collection of accounts receivable from Edwards, an investment in the TMR business of $2,089,000 relating to the payment to Edwards of earn-out purchase consideration, and an investment of approximately $436,000 in property, plant and equipment.

As at March 31, 2008 there were a total of 24,533,982 common shares (26,094,395 on a fully diluted basis) and no preferred shares outstanding. As at March 31, 2008 a total of 1,560,413 stock options were outstanding under the Company's employee stock option plan.

Conference call

Novadaq will host a conference call on Monday, May 12, 2008 at 10:00 a.m. EST to discuss the financial results for the first quarter ended March 31, 2008. To access the conference call by telephone, dial 416-644-3422 or 1-800-731-5319. Please connect approximately ten minutes prior to the beginning of the call to ensure participation. The conference call will be archived for replay until May 19, 2008 at midnight. To access the archived conference call, dial 416-640-1917 or 1-877-289-8525 and enter the reservation number 21270216 followed by the number sign.

A live audio webcast of the conference call will be available at http://www.novadaq.com. Please connect at least ten minutes prior to the conference call to ensure adequate time for any software download that may be required to join the webcast. The webcast will be archived at the above website for 365 days.
For complete financial results, please see our filings at http://www.sedar.com.

About Novadaq Technologies

Novadaq Technologies Inc. commercializes real-time imaging and image guidance systems for use in the operating room. With one set of proprietary core technologies, Novadaq's products have multiple applications. Novadaq's SPY System enables cardiac surgeons to diagnose intra-operatively by visually assessing coronary vasculature and bypass graft functionality during the course of heart bypass surgery. The SPY System is also indicated for use during other surgeries, such as cardiovascular, plastic, reconstructive, organ transplant and urological procedures. SPY can be used to visualize blood vessels, tumors, tumor margins and the lymphatic system. Novadaq introduced PINPOINT, its first minimally invasive imaging system for autofluorescence in October 2007. PINPOINT allows surgeons to differentiate between healthy and cancerous tissue in the lung and other hollow organs. Further expanding its portfolio of minimally invasive products, Novadaq is developing SPYscope which combines the typical features of a standard endoscope with the additional capabilities of SPY imaging. Novadaq is the exclusive United States distributor of PLC Medical's CO2 HEART LASER System, used in the same cardiac procedures as the SPY System. Novadaq also offers the OPTTX(R) System, which leverages the company(1)s core imaging technology and is designed for the diagnosis, evaluation and treatment of wet Age-related Macular Degeneration (AMD). For more information, please visit the company's website at http://www.novadaq.com.

Forward looking Statements

Certain statements included in this press release may be considered forward-looking. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on Novadaq's current beliefs as well as assumptions made by and information currently available to Novadaq and relate to, among other things, results of future clinical tests of PINPOINT and the SPY System, anticipated financial performance, business prospects, strategies, regulatory developments, market acceptance and future commitments. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by Novadaq in its public securities filings actual events may differ materially from current expectations. Novadaq disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

CONSOLIDATED BALANCE SHEET

(expressed in U.S. $)

Unaudited

March 31, December 31,

2008 2007

$ $

--------------------------

ASSETS

Current

Cash and cash equivalents 7,514,062 7,417,929

Short-term investments 7,261,108 11,443,506

Accounts receivable 2,259,637 4,743,994

Current portion of prepaid expenses and

other receivables 1,119,484 1,185,707

Inventory 1,744,899 2,031,932

--------------------------

Total current assets 19,899,190 26,823,068

--------------------------

Long-term investments 426,000 426,000

Long-term receivable 52,312 -

Property, plant and equipment, net 2,942,731 2,785,342

Prepaid expenses 340,290 323,761

Deferred development costs 331,183 331,183

Intangible assets 10,722,513 11,030,760

--------------------------

34,714,219 41,720,114

--------------------------

--------------------------

LIABILITIES AND SHAREHOLDERS' EQUITY

Current

Accounts payable and accrued liabilities 3,991,841 6,289,722

Current portion of deferred revenue 908,729 995,099

--------------------------

Total current liabilities 4,900,570 7,284,821

--------------------------

Deferred revenue 461,145 446,118

--------------------------

Total liabilities 5,361,715 7,730,939

--------------------------

Shareholders' equity

Share capital 80,134,644 80,109,644

Contributed surplus 4,462,448 4,285,187

Accumulated other comprehensive loss (69,000) (69,000)

Deficit (55,175,588) (50,336,656)

--------------------------

Total shareholders' equity 29,352,504 33,989,175

--------------------------

34,714,219 41,720,114

--------------------------

--------------------------

CONSOLIDATED STATEMENTS OF LOSS AND

COMPREHENSIVE LOSS AND DEFICIT

(expressed in U.S. $)

Unaudited

Three months Three months

ended ended

March 31, March 31,

2008 2007

$ $

--------------------------

Revenues

Product sales 2,414,585 1,427,424

Service revenue 358,077 -

--------------------------

Total revenues 2,772,662 1,427,424

Cost of sales 1,468,191 748,062

--------------------------

Gross profit 1,304,471 679,362

--------------------------

Operating expenses

Sales and marketing 2,784,126 2,216,885

Research and development 1,612,091 1,294,876

General and administration 1,459,018 878,466

Depreciation 88,815 51,955

Amortization 308,247 121,522

Loss on foreign exchange 49,526 1,418

--------------------------

6,301,823 4,565,122

--------------------------

Loss before the following (4,997,352) (3,885,760)

Interest expense - (9,396)

Interest income 158,420 194,023

--------------------------

Net loss and comprehensive loss for the period (4,838,932) (3,701,133)

Deficit, beginning of period (50,336,656) (34,675,721)

--------------------------

Deficit, end of period (55,175,588) (38,376,854)

--------------------------

--------------------------

Basic and fully diluted loss per share (0.20) (0.19)

--------------------------

--------------------------

CONSOLIDATED STATEMENTS OF CASH FLOWS

(expressed in U.S. $)

Unaudited

Three months Three months

ended ended

March 31, March
'/>"/>

SOURCE Novadaq Technologies Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Novadaq Resumes Normal Business Operations by Securing ICG for SPY
2. Novadaq launches PINPOINT: Companys first minimally invasive imaging system
3. Novadaq announces third quarter 2007 conference call and webcast
4. Novadaq to present at Piper Jaffray Healthcare Conference
5. Novadaq to present at BMO Healthcare Conference
6. Novadaqs SPY Imaging System named Product of the Year by Frost and Sullivan
7. Novadaqs SPY System receives clearance for use in organ transplant surgery
8. Novadaq Data Presented at 2008 Society of Thoracic Surgeons Meeting
9. NOVADAQs SPY System to be Featured During Live Broadcast of Robotic Surgery
10. Novadaq to present at Cowen Healthcare Conference
11. Novadaq to hold fiscal 2007 year-end and fourth quarter results conference call and webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... NY & Salt Lake City, UT (PRWEB) , ... February 05, ... ... Founder of Activz Whole-Food Nutrition , announced that the much-anticipated feature with author ... the New Really Cool Humans Amateur TV Network. , Each week, on his weekly ...
(Date:2/5/2016)... ... February 05, 2016 , ... The event is being held ... Event Center in Minneapolis, Minn. Triumph Over Parkinson’s will fund nearly $100,000 for research ... Schneiderman’s Furniture, lives with Parkinson’s disease and is the architect of this informative event ...
(Date:2/5/2016)... ... February 05, 2016 , ... ... addition of micro-needling services in their Napa Valley office. The technique utilizes the ... Surgery Associates, Dr. Canales and Dr. Furnas, are part of only a select ...
(Date:2/5/2016)... ... February 05, 2016 , ... ... H. Van Allen have signed a joint enrollment and degree completion agreement. ... toward associate and baccalaureate degrees at FHU|Dickson. , The agreement allows students ...
(Date:2/5/2016)... ... February 05, 2016 , ... ... exclusively to funding innovative lymphoma research and serving the lymphoma community through a ... to once again host, Swirl, A Wine Tasting Event at the La Gorce ...
Breaking Medicine News(10 mins):
(Date:2/4/2016)... , Feb. 4, 2016 Summary Breast ... cancer and the most common cancer in women worldwide, ... disease exceedingly prevalent. The number of women diagnosed with ... but the number of deaths has declined due to ... treatment has been revolutionized in the past four decades, ...
(Date:2/4/2016)... Feb. 4, 2016 Mettler-Toledo International Inc. (NYSE: ... 2015.  Provided below are the highlights: , ... compared with the prior year.  Reported sales decreased 3% ... quarter. , Net earnings per diluted share as ... prior- year period.  Adjusted EPS was $4.65, an increase ...
(Date:2/4/2016)... 2016  Blueprint Medicines Corporation (NASDAQ: BPMC ... selective investigational kinase medicines for patients with genomically ... board of directors of Lonnel Coats , ... of industry-related experience. Jeffrey Albers ... strong strategic experience developing and commercializing numerous oncology ...
Breaking Medicine Technology: